Hematologic Oncology

Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.

Amer Zeidan, MBBS, and Rami Komrokji, MD, offer closing remarks on recent advances in MF and MDS, and look towards the future of treatment.

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Expert perspective on the role of a pharmacist in managing patients with identified tumor lysis syndrome.

Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.

Anthony Perissinotti, PharmD, BCOP, highlights associated risk for tumor lysis syndrome and identifies signs and symptoms.

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

Topline results from the phase 1 European MB-105 clinical trial showed that new safety results for annamycin, a next-generation anthracycline, are in keeping with previous findings for patients with relapsed/refractory acute myeloid leukemia.

The combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cell lymphoma, according to preliminary findings from the phase 2b VITALIZE trial.

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

The CAR T-cell therapy brexucabtagene autoleucel produced a median overall survival of 26 months in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.

Dr Komrokji leads a discussion on emerging data on how p53 mutations and chromosome 5q deletions may affect prognosis, treatment response, and outcomes for patients with MDS.

Expert panelists reflect on the case presented by Dr Garcia-Manero and share their unique perspectives on how they might have approached treatment and followup for this patient in their own practice.

In this fifth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, reviews the implications of up-front vs delayed transplant on survival, quality of life, and risk of secondary malignancies in newly diagnosed, multiple myeloma.

Dr Komrokji summarizes the remaining unmet needs in the treatment of MF, including suboptimal responses to JAK2 inhibitors, and comments on data from ongoing trials that may address these needs.

A comprehensive review of the treatment landscape for myelofibrosis (MF) and recent ASCO and ASH data updates on JAK2 inhibitors.

Treatment with crovalimab led to disease control through transfusion avoidance and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who have not been previously treated with complement inhibitors.

Closing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.

Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.

A brief review of the differences that might be observed between tumor lysis syndrome management in an academic versus community setting.